Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

Most women continued using oral minoxidil for hair loss despite mild to moderate side effects.

This study reported that 57% of healthcare workers experienced persistent post-COVID-19 complications, with common symptoms including hair loss, easy fatigability, mood swings, and anxiety.

Low-dose oral minoxidil can cause dizziness in women without lowering blood pressure, so careful monitoring is needed.

In this retrospective study, researchers found that while combination therapy of spironolactone and oral minoxidil for female alopecia commonly led to mild outpatient-manageable side effects, starting both medications simultaneously reduced hypertrichosis risk, but taking multiple blood pressure medications increased hypotensive symptoms.

Low-glycemic index diets are beneficial for weight loss and satiety, but more research is needed on long-term effects and individualized approaches are recommended.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

This study observed a slight reduction in blood pressure in normotensive patients after taking a 5-mg dose of oral minoxidil, particularly within the first two hours and more so in those with high baseline blood pressure.

This article reviews the causes and treatments of hirsutism, emphasizing the importance of considering ethnic and cultural norms when interpreting grading systems, and reports no new original findings.

This commentary explores the challenges and considerations in treating female pattern hair loss, with no new clinical findings reported.

The document concludes that skin and nail changes can indicate various underlying health conditions.

This case report describes two women experiencing hormonally associated vestibulodynia and female arousal disorder, potentially linked to the use of spironolactone for androgen-mediated cutaneous disorders.

This study found no baseline factors that predicted flibanserin efficacy for HSDD, though low testosterone or use of hormonal contraceptives were associated with reduced efficacy.

Propranolol can cause reversible hair loss.

This review discusses the side effects and monitoring guidelines for commonly prescribed systemic acne treatments and reports no new clinical findings.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

This article reviews common hair growth abnormalities in children, emphasizing the importance of distinguishing normal development from potential signs of metabolic disorders and indicates no new clinical results.

This article reviews the current literature on rosacea, focusing on the new subtype classification system and the main theories of its pathogenesis, but reports no new clinical results.

This study found that maintenance treatment with diphenylcyclopropenone was associated with a lower relapse rate in alopecia areata patients, highlighting the importance of adjusting treatment intervals post-improvement.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

This review concluded that low-dose oral minoxidil is an effective and well-tolerated treatment for male androgenetic alopecia, with significant hair density improvements and manageable side effects.

In this study, patients with seasonal affective disorder were found to have increased functional connectivity in certain brain networks and higher low-frequency fluctuations compared to healthy controls, which aligns with their attentional and psychomotor symptoms.

This chapter details the causes and diagnostic process of pediatric alopecia, including trichoscopic findings, but reports no new clinical results.

Hair loss in children can be caused by fungal infections, trauma, autoimmune disorders, or stress, and treatments vary depending on the cause.

This study found high levels of toxic heavy metals in water sources of mining communities in Abakaliki, Nigeria, posing potential health risks including Parkinson's and Alzheimer's diseases.

This literature study reviews the consequences of hair loss due to chemotherapy and nursing care interventions but reports no new clinical results.

Minoxidil promotes hair growth in male pattern baldness.

Many COVID-19 survivors experience long-term symptoms like fatigue and sleep issues, needing ongoing medical support.

This review examines skin symptoms, diagnosis, and treatment of zinc deficiency in children, proposing a classification system but reporting no new clinical results.